Enter assignee name

EPO Patents = 2

Trademarks = 1

Forward Citations = 3

Loading Chart...

12 inventors (with patents filed for the assignee):

Pan Zheng (7 out of 30 patents)

Martin Devenport (7 out of 13 patents)

Yang Liu (7 out of 33 patents)

4. Xuexiang Du (4 out of 4 patents)

5. Mingyue Liu (4 out of 6 patents)

6. Fei Tang (4 out of 4 patents)

7. Wei Wu (3 out of 27 patents)

8. Rhonda Flores (1 out of 1 patent)

9. Peiying Ye (1 out of 1 patent)

10. Zhihong Xue (1 out of 1 patent)

11. Hung-Yen Chou (1 out of 1 patent)

12. Yan Zhang (1 out of 1 patent)

7 patents: Sort by Forward Citations

1. 12473362 - Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof (2025-11-18),

2. 12441780 - CD80 and CD86 binding protein compositions and uses thereof (2025-10-14),

3. 12286485 - Anti-CD24 compositions and uses thereof (2025-04-29),

4. 12227557 - CD80 and CD86 binding protein compositions and uses thereof (2025-02-18),

5. 12129299 - Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects (2024-10-29),

6. 11629188 - Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof (2023-04-18),

7. 11261233 - CD80 and CD86 binding protein compositions and uses thereof (2022-03-01),

Oncoc4, Inc. is a biotechnology company specializing in the development of innovative cancer therapies. The company focuses on the discovery and advancement of novel compounds that target cancer cell metabolism and signaling pathways, aiming to improve treatment outcomes for patients. With a team of experienced scientists and industry experts, Oncoc4, Inc. is committed to transforming cancer care through research, collaboration, and clinical development. The company's lead product candidates are currently in various stages of preclinical and clinical trials, demonstrating potential for significant therapeutic benefits. Oncoc4, Inc. is dedicated to addressing unmet needs in oncology and advancing the frontiers of cancer treatment through precision medicine and targeted therapies.

This text is generated by artificial intelligence and may not be accurate.